Urgent.News

600+ sources. One page. See who else covered it.

Editions

Health & Medicine

GDUFA IV commitments: New onshoring incentives and meeting types for generic drugs

From 2028 to 2032, generic drug applicants will continue to see many of the same FDA review timelines as they did over the last five years, but new initiatives related to onshore manufacturing and new ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Wednesday 12 August →